Orlando, Fla: A stem cell therapy for treating patients experiencing moderate to severe heart failure showed real promise in preventing serious consequences or death, according to data from a small mid-stage clinical trial.The treatment from Australia`s Mesoblast Ltd, known as revascor, appeared to be safe and reduced by 78 percent the rate of major adverse events -- heart attacks, cardiac death and need for artery clearing procedures -- after one year compared with patients who received the standard of care.The findings from the 60-patient trial presented on Monday at the American Heart Association scientific meeting in Orlando were deemed to be statistically significant, despite the small size of the study."It is extremely surprising and really incredible to see that there are less cardiac deaths and less MACE (major adverse cardiac events) events in the treated population and that is over a long period of follow-up, in some patients close to three years, so that`s very impressive," said Dr Emerson Perin, the study`s lead investigator."If we have the same findings in a larger study, we think we`ve got something that will be an approvable therapy," Perin, from the Texas Heart Institute in Houston, said in an interview.
Is cheese better than butter for heart health?
Brain scan study finds evidence of `chemo brain`